Biomarkers of HIV-1 associated dementia: Proteomic investigation of sera

Jayme Wiederin, Wojciech Rozek, Fenghai Duan, Pawel S Ciborowski

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: New, more sensitive and specific biomarkers are needed to support other means of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/serum, including that there is no one proteomic platform that can offer complete identification of differences in proteomic profiles. Another set of problems is associated with heterogeneity of human samples in addition intrinsic variability associated with every step of proteomic investigation. Validation is the very last step of proteomic investigation and it is very often difficult to validate potential biomarker with desired sensitivity and specificity. Even though it may be possible to validate a differentially expressed protein, it may not necessarily prove to be a valid diagnostic biomarker. Results: In the current study we report results of proteomic analysis of sera from HIV-infected individuals with or without cognitive impairment. Application of SELDI-TOF analysis followed by weak cation exchange chromatography and 1-dimensional electrophoresis led to discovery of gelsolin and prealbumin as differentially expressed proteins which were not detected in this cohort of samples when previously investigated by 2-dimensional electrophoresis with Difference Gel Electrophoresis technology. Conclusion: Validation using western-blot analysis led us to conclude that relative change of the levels of these proteins in one patient during a timeframe might be more informative, sensitive and specific than application of average level estimated based on an even larger cohort of patients.

Original languageEnglish (US)
Article number8
JournalProteome Science
Volume7
DOIs
StatePublished - Mar 17 2009

Fingerprint

Biomarkers
Proteomics
Dementia
HIV-1
Electrophoresis
Serum
Two-Dimensional Difference Gel Electrophoresis
Gelsolin
Plasma (human)
Technology
Proteins
Prealbumin
Chromatography
Neurodegenerative Diseases
Cations
Western Blotting
Gels
HIV
Sensitivity and Specificity

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Biomarkers of HIV-1 associated dementia : Proteomic investigation of sera. / Wiederin, Jayme; Rozek, Wojciech; Duan, Fenghai; Ciborowski, Pawel S.

In: Proteome Science, Vol. 7, 8, 17.03.2009.

Research output: Contribution to journalArticle

Wiederin, Jayme ; Rozek, Wojciech ; Duan, Fenghai ; Ciborowski, Pawel S. / Biomarkers of HIV-1 associated dementia : Proteomic investigation of sera. In: Proteome Science. 2009 ; Vol. 7.
@article{dac8f19e44864a858ea475ad5af184b5,
title = "Biomarkers of HIV-1 associated dementia: Proteomic investigation of sera",
abstract = "Background: New, more sensitive and specific biomarkers are needed to support other means of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/serum, including that there is no one proteomic platform that can offer complete identification of differences in proteomic profiles. Another set of problems is associated with heterogeneity of human samples in addition intrinsic variability associated with every step of proteomic investigation. Validation is the very last step of proteomic investigation and it is very often difficult to validate potential biomarker with desired sensitivity and specificity. Even though it may be possible to validate a differentially expressed protein, it may not necessarily prove to be a valid diagnostic biomarker. Results: In the current study we report results of proteomic analysis of sera from HIV-infected individuals with or without cognitive impairment. Application of SELDI-TOF analysis followed by weak cation exchange chromatography and 1-dimensional electrophoresis led to discovery of gelsolin and prealbumin as differentially expressed proteins which were not detected in this cohort of samples when previously investigated by 2-dimensional electrophoresis with Difference Gel Electrophoresis technology. Conclusion: Validation using western-blot analysis led us to conclude that relative change of the levels of these proteins in one patient during a timeframe might be more informative, sensitive and specific than application of average level estimated based on an even larger cohort of patients.",
author = "Jayme Wiederin and Wojciech Rozek and Fenghai Duan and Ciborowski, {Pawel S}",
year = "2009",
month = "3",
day = "17",
doi = "10.1186/1477-5956-7-8",
language = "English (US)",
volume = "7",
journal = "Proteome Science",
issn = "1477-5956",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Biomarkers of HIV-1 associated dementia

T2 - Proteomic investigation of sera

AU - Wiederin, Jayme

AU - Rozek, Wojciech

AU - Duan, Fenghai

AU - Ciborowski, Pawel S

PY - 2009/3/17

Y1 - 2009/3/17

N2 - Background: New, more sensitive and specific biomarkers are needed to support other means of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/serum, including that there is no one proteomic platform that can offer complete identification of differences in proteomic profiles. Another set of problems is associated with heterogeneity of human samples in addition intrinsic variability associated with every step of proteomic investigation. Validation is the very last step of proteomic investigation and it is very often difficult to validate potential biomarker with desired sensitivity and specificity. Even though it may be possible to validate a differentially expressed protein, it may not necessarily prove to be a valid diagnostic biomarker. Results: In the current study we report results of proteomic analysis of sera from HIV-infected individuals with or without cognitive impairment. Application of SELDI-TOF analysis followed by weak cation exchange chromatography and 1-dimensional electrophoresis led to discovery of gelsolin and prealbumin as differentially expressed proteins which were not detected in this cohort of samples when previously investigated by 2-dimensional electrophoresis with Difference Gel Electrophoresis technology. Conclusion: Validation using western-blot analysis led us to conclude that relative change of the levels of these proteins in one patient during a timeframe might be more informative, sensitive and specific than application of average level estimated based on an even larger cohort of patients.

AB - Background: New, more sensitive and specific biomarkers are needed to support other means of clinical diagnosis of neurodegenerative disorders. Proteomics technology is widely used in discovering new biomarkers. There are several difficulties with in-depth analysis of human plasma/serum, including that there is no one proteomic platform that can offer complete identification of differences in proteomic profiles. Another set of problems is associated with heterogeneity of human samples in addition intrinsic variability associated with every step of proteomic investigation. Validation is the very last step of proteomic investigation and it is very often difficult to validate potential biomarker with desired sensitivity and specificity. Even though it may be possible to validate a differentially expressed protein, it may not necessarily prove to be a valid diagnostic biomarker. Results: In the current study we report results of proteomic analysis of sera from HIV-infected individuals with or without cognitive impairment. Application of SELDI-TOF analysis followed by weak cation exchange chromatography and 1-dimensional electrophoresis led to discovery of gelsolin and prealbumin as differentially expressed proteins which were not detected in this cohort of samples when previously investigated by 2-dimensional electrophoresis with Difference Gel Electrophoresis technology. Conclusion: Validation using western-blot analysis led us to conclude that relative change of the levels of these proteins in one patient during a timeframe might be more informative, sensitive and specific than application of average level estimated based on an even larger cohort of patients.

UR - http://www.scopus.com/inward/record.url?scp=64749112492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64749112492&partnerID=8YFLogxK

U2 - 10.1186/1477-5956-7-8

DO - 10.1186/1477-5956-7-8

M3 - Article

C2 - 19292902

AN - SCOPUS:64749112492

VL - 7

JO - Proteome Science

JF - Proteome Science

SN - 1477-5956

M1 - 8

ER -